10-Q: Vaxart Reports Q1 2026 Financials, Focus on COVID-19 and Norovirus Vaccines

Vaxart, Inc. reported Q1 2026 results, showing increased revenue driven by government contracts, while continuing development of its oral COVID-19 and norovirus vaccine candidates.

Summary

• Vaxart, Inc. reported Q1 2026 financial results, with total revenue increasing by 88% year-over-year to $39.2 million, primarily driven by a significant increase in revenue from government contracts.
• Operating expenses decreased by 5% to $34.1 million, leading to an operating income of $5.2 million, a substantial improvement from the $14.9 million operating loss in the prior year's quarter.
• Net income for the quarter was $5.2 million, or $0.02 per diluted share, a significant turnaround from a net loss of $15.6 million in Q1 2025.
• The company's cash, cash equivalents, and short-term investments stood at $61.0 million as of March 31, 2026, providing sufficient runway for at least 12 months.
• Vaxart continues to advance its oral vaccine candidates, including a COVID-19 vaccine in a Phase 2b study and a second-generation norovirus vaccine candidate progressing towards further clinical development.
• A new Non-Employee Director Compensation Program was adopted effective March 10, 2026, outlining cash and equity compensation for non-employee board members.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic. The significant revenue growth and return to profitability are strong positives, but the ongoing challenges with the COVID-19 trial funding and the delisting from Nasdaq introduce considerable risk.

Positives

• Total revenue increased by 88% to $39.2 million in Q1 2026 compared to $20.9 million in Q1 2025.
• Revenue from government contracts more than doubled to $36.4 million from $19.3 million.
• Operating income turned positive at $5.2 million, a significant improvement from an operating loss of $14.9 million in the prior year.
• Net income was $5.2 million, a substantial turnaround from a net loss of $15.6 million in Q1 2025.
• Cash, cash equivalents, and short-term investments totaled $61.0 million as of March 31, 2026, providing at least 12 months of operating runway.
• The company has sufficient cash runway into the second quarter of 2027 based on management's current plan.
• The Phase 1 study for the second-generation norovirus vaccine constructs showed promising results with increased antibody titers.
• The COVID-19 Phase 2b study's sentinel cohort data was recommended to proceed without modifications by the independent data safety monitoring board.
• A new Non-Employee Director Compensation Program was established to attract and retain qualified board members, including cash retainers and equity awards.

Negatives

• Non-cash royalty revenue related to the sale of future royalties decreased significantly by 97% to $42,000 from $1.6 million.
• The COVID-19 Phase 2b study experienced a stop-work order in August 2025, leading to reduced enrollment and anticipated reduction in contract funding.
• The company's common stock was delisted from The Nasdaq Capital Market in July 2025, impacting trading liquidity and potentially financing options.
• The company anticipates needing to raise additional capital, which may result in further dilution to stockholders.
• The cumulative remaining shortfall amount related to the sale of future royalties was $6.7 million as of March 31, 2026.

Risks

• The company's reliance on government funding, particularly from HHS BARDA for its COVID-19 vaccine candidate, poses a risk if funding is reduced, eliminated, or delayed.
• The stop-work orders on the COVID-19 Phase 2b study could lead to reduced contract funding and impact the development timeline.
• The delisting from Nasdaq and trading on OTCQX may limit liquidity and hinder the ability to raise capital.
• There is no guarantee that the collaboration with Dynavax (now a Sanofi subsidiary) will be successful or that Dynavax will elect to assume further development responsibilities.
• Changes in the regulatory environment for vaccines could adversely impact product development and commercialization efforts.
• The company may not be able to realize the potential benefits of its collaborations.
• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company faces risks related to the development and commercialization of its product candidates, including clinical trial outcomes, competition, and market acceptance.

Future Outlook

The company expects to have sufficient cash runway into the second quarter of 2027 based on management's current plan. Future capital requirements will depend on factors such as the timing and costs of preclinical and clinical trials, manufacturing capabilities, royalty income, regulatory approvals, and potential collaborations. The company anticipates a further modification to the 2024 ATI-RRPV Contract to reflect a reduced scope of work and funding due to previous stop-work orders.

Management Comments

• Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement.
• Management concluded that the conditions and events that previously raised substantial doubt about the company's ability to continue as a going concern have been alleviated.
• The company's oral vaccines are designed to generate broad and durable immune responses that may protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer.
• Based on our norovirus clinical data findings to date, our norovirus oral vaccination induces mucosal and systemic immune responses.
• We believe that a functional fecal IgA response is probably critical for protection against norovirus infection.
• Sanofi can be expected to make their decision for further investments in our Dynavax partnered COVID-19 vaccine and potentially other Vaxart assets in the context of this larger vaccine portfolio.

Industry Context

StockSavvy.ai notes that Vaxart's Q1 2026 results reflect a significant shift towards government contract revenue, a common trend in the biotechnology sector, especially for companies developing vaccines for public health threats like COVID-19. The company's focus on oral vaccine delivery platforms continues to be a key differentiator in a market dominated by injectable vaccines. The ongoing development of both COVID-19 and norovirus vaccines positions Vaxart to address significant unmet medical needs, though the reliance on government funding and the challenges in clinical trial progression highlight the inherent risks in this industry.

Comparison to Industry Standards

• Vaxart's revenue growth of 88% in Q1 2026, driven by government contracts, is strong but specific comparisons to industry peers are difficult without knowing the exact nature and scale of the government contracts relative to typical biotech revenue streams.
• The shift from operating loss to operating income is a positive development, but the overall profitability and cash burn rate need to be assessed against industry benchmarks for clinical-stage biotechnology companies.
• The company's cash runway of at least 12 months is a critical metric. Many clinical-stage biotechs aim for 18-24 months to provide sufficient time for development milestones. Vaxart's projected runway into Q2 2027 is a positive sign, but the need for future capital raises remains a key consideration.
• The development of an oral COVID-19 vaccine candidate faces competition from established mRNA vaccines (Pfizer-BioNTech, Moderna) and other emerging technologies. Vaxart's differentiation lies in its oral delivery platform, which aims for improved patient compliance and potentially broader immune responses.
• The norovirus vaccine development is in a less crowded field compared to COVID-19. However, the FDA's request for new clinical data indicates a higher bar for approval than initially anticipated, a common challenge in vaccine development.

Management Changes

Corporate Governance

Legal Proceedings

• Securities class action lawsuits filed in August and September 2020 (Himmelberg v. Vaxart, Inc. et al. and Hovhannisyan v. Vaxart, Inc. et al.) were partially settled for $12.0 million, with $2.0 million paid by the company and the remainder by insurers. Claims against Armistice Capital, LLC proceeded to a jury trial which concluded with a verdict in favor of Armistice.
• A lawsuit (Roth v. Armistice Capital LLC, et al.) concerning short-swing profits was dismissed by the court, and subsequent appeals affirmed the dismissal.
• A purported shareholder lawsuit (Chan v. Vaxart, Inc. et al.) opting out of the class actions has been stayed.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Shareholders may be impacted by the delisting from Nasdaq and reduced trading liquidity.
• Employees and directors will be compensated under the new Non-Employee Director Compensation Program, which includes equity awards designed to align interests.

Next Steps

• Advance the norovirus program to the next stage of clinical development in 2026, pending partnership or other funding.
• Continue to collect participant data over a 12-month period post-vaccination for the COVID-19 Phase 2b study.
• Anticipate a further modification to the 2024 ATI-RRPV Contract reflecting reduced scope and funding.
• Deliver the end-of-Phase 2 data package for the COVID-19 vaccine candidate to Dynavax.
• Conduct a planned end-of-Phase 2 meeting with the FDA for the COVID-19 vaccine candidate.
• File a registration statement with the SEC covering the resale by LPC of shares purchased under the April 2026 ELOC.
• Continue development of the preclinical tri-valent seasonal influenza vaccine candidate.
• Make a regulatory filing to proceed with clinical trials for an HPV vaccine candidate.

Key Dates

Recommendation

Vaxart's Q1 2026 results show a significant financial turnaround with increased revenue and profitability, driven by government contracts. The company's pipeline, particularly the norovirus and COVID-19 vaccine candidates, remains promising. However, the delisting from Nasdaq, ongoing challenges with COVID-19 trial funding, and the need for future capital raises introduce substantial risks. The collaboration with Sanofi (via Dynavax) offers potential but is not guaranteed. Therefore, a 'hold' recommendation is appropriate, balancing the positive operational improvements against the significant execution and funding risks.

Keywords

Vaxart, Form 10-Q, Quarterly Report, Biotechnology, Vaccine Development, COVID-19 Vaccine, Norovirus Vaccine, Government Contracts, HHS BARDA, Clinical Trials, Financial Results, SEC Filing